A Phase I/II Study of Celecoxib and Erlotinib Hydrochloride as Adjuvant Therapy for High Risk Patients With a History of Hepatocellular Carcinoma.

Trial Profile

A Phase I/II Study of Celecoxib and Erlotinib Hydrochloride as Adjuvant Therapy for High Risk Patients With a History of Hepatocellular Carcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2012

At a glance

  • Drugs Celecoxib (Primary) ; Erlotinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 11 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top